[company_age]10.0[/company_age][employees]11-50 employees[/employees][funding]Series B[/funding][description]Novigenix is a Swiss precision medicine company specializing in Immuno-Transcriptomic solutions for early detection of disease, development of novel therapeutics, and drug target discovery. The company's proprietary LITOSeek™ platform is an AI-enabled RNA analytic platform optimized for mapping the response of the immune system to onset and progression of disease. Novigenix's analytical pipelines integrate patient multi-omics data with advanced Machine Learning and artificial intelligence approaches to provide actionable insights and precision solutions. The company's liquid biopsy products and services include a suite of biopharma solutions for clinical development of novel therapies, drug target discovery, and early detection of Colorectal Cancer. Novigenix provides services to Pharma and Biotech customers by leveraging the proprietary LITOSeek™ data analytics and patient clinical data platform to deliver previously unknown insights into heterogeneity of patient response and development of actionable biomarkers for optimization of new therapeutic modalities. Novigenix's unique approach to Immuno-Transcriptomics and its proprietary LITOSeek™ platform set it apart from its competitors in the precision medicine field.[/description][ps]Immuno-Transcriptomic solutions for early detection of disease, development of novel therapeutics, and drug target discovery.[/ps]